4basebio (LON:4BB) Stock Price Down 2.2% – Time to Sell?

4basebio PLC (LON:4BB) shares dropped 2.2% during mid-day trading on Friday . The company traded as low as GBX 1,100 ($14.65) and last traded at GBX 1,100 ($14.65). Approximately 693 shares changed hands during mid-day trading, a decline of 36% from the average daily volume of 1,077 shares. The stock had previously closed at GBX 1,125 ($14.98).

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada reissued an “outperform” rating and set a GBX 1,600 ($21.30) price target on shares of 4basebio in a research note on Thursday, March 13th.

4basebio Trading Down 2.2 %

The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The firm’s 50-day moving average is GBX 1,135.49 and its 200 day moving average is GBX 1,202.90. The firm has a market capitalization of £140.91 million, a price-to-earnings ratio of -1,410.26 and a beta of 1.09.

Insider Transactions at 4basebio

In other news, insider Amy Walker purchased 1,151 shares of the stock in a transaction on Friday, February 28th. The stock was purchased at an average price of GBX 1,120 ($14.91) per share, for a total transaction of £12,891.20 ($17,165.38). Also, insider Heikki Lanckriet purchased 2,400 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The stock was purchased at an average price of GBX 1,205 ($16.05) per share, for a total transaction of £28,920 ($38,508.66). 68.44% of the stock is owned by company insiders.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.